46Merkel cell polyomavirus (MCV) small T antigen (sT) is the main oncoprotein for the 47 development of Merkel cell carcinoma (MCC). MCC is a rare, clinically aggressive 48 neuroendocrine tumor of the skin with a high propensity for local, regional, and distant 49 spread. The expression of matrix metalloproteinase (MMP)-9 has been implicated as 50 playing an important role in cell invasion and metastasis in many human cancers. 51Previously, MCV sT has been shown to increase the cell migration and invasiveness of 52 MCC cells through the transcriptional activation of the sheddase molecule, ADAM 10 (A 53 disintergrin and metalloprotease domain-containing protein 10). In this study, we show 54 that MCV sT protein stimulates epithelial-mesenchymal transition (EMT) gene 55 expression, including MMP-9. This effect is dependent on the presence of the large 56 stabilization domain (LSD), which is known to be responsible for cell transformation 57 through targeting of promiscuous E3 ligases, including FBW7, a known MMP-9 58 regulator. Chemical treatments of MMP-9 markedly inhibited sT-induced cell migration 59 and invasion. These results suggest that sT contributes to the activation of MMP-9 as a 60 result of FBW7 targeting, and increases the invasive potential of cells, which can be 61 used for a targeted therapeutic intervention. 62
63
IMPORTANCE 64Merkel cell carcinoma (MCC) is the most aggressive cutaneous tumor without clearly 65 defined treatment. Although MCC has high propensity for metastasis, little is known about 66 the underlying mechanisms that drive MCC invasion and metastatic progression. MMP-9 67 has shown to play a detrimental role in many metastatic human cancers, including 68 melanoma and other non-melanoma skin cancers. Our study discovers that MCV sT-69 mediated MMP-9 activation is driven through the LSD, a known E3 ligase targeting 70 domain, in MCC. MMP-9 may serve as the biochemical culprit to target and develop a 71 novel approach for the treatment of metastatic MCC. 72 5333. Kaae J, Hansen AV, Biggar RJ, Boyd HA, Moore PS, Wohlfahrt J, Melbye M. 534